Transarterial chemoembolization of hepatocellular carcinoma. Agents and drugs: an overview. Part 1

Bibliography

• Parkin DM, Bray F, Ferlay J, Estimating the world cancer burden: globocan 2000. Int J Cancer 2001;94:153-6
   PubMed Web of Science ®Google Scholar
• Ferenci P, Fried M, Labrecque D, World gastroenterology organisation guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis 2010;19:311-07
   PubMed Web of Science ®Google Scholar
• Ferenci P, Fried M, Labrecque D, Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 2010;44:239-45
   PubMed Web of Science ®Google Scholar
• Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma – epidemiological trends and risk factors. Dig Dis 2009;27:80-92
   PubMed Web of Science ®Google Scholar
• Bosch FX, Ribes J, Cléries R, Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005;9:191-211
   PubMed Web of Science ®Google Scholar
• Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma from palliation to cure. Cancer 2006;106:1653-61
   PubMed Web of Science ®Google Scholar
• Ma S, Jiao B, Liu X, Approach to radiation therapy in hepatocellular carcinoma. Cancer Treat Rev 2010;36:157-63
   PubMed Web of Science ®Google Scholar
• Santi V, Buccione D, Di Micoli A, The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol 2012;5:397-405
   Google Scholar
• O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. Hepatology 2010;51:307-28
   PubMed Web of Science ®Google Scholar
• Hassan MM, Hwang LY, Hatten CJ, Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206-13
   PubMed Web of Science ®Google Scholar
• Velazquez RF, Rodriguez M, Navascues CA, Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 2003;37:520-7
   PubMed Web of Science ®Google Scholar
• de Lope CR, Tremosini S, Forner A, Management of HCC. J Hepatol 2012;56(Suppl 1):S75-87
   PubMed Web of Science ®Google Scholar
• Erez A, Shchelochkov OA, Plon SE, Insights into the pathogenesis and treatment of cancer from inborn errors of metabolism. Am J Hum Genet 2011;88:402-21
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2
   PubMed Web of Science ®Google Scholar
• Munoz N, Bosch FX. Epidemiology of hepatocellular carcinoma. In: Okuda K, Ishak K, editors. Neoplasms of the liver. Springer, Tokyo; 1989. p. 3-19
   Google Scholar
• Wörns MA, Galle PR. Future perspectives in hepatocellular carcinoma. Dig Liver Dis 2010;42S:S302-9
   Google Scholar
• Raoul JL, Sangro B, Forner A, Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011;37:212-20
   PubMed Web of Science ®Google Scholar
• Thomas MB, Jaffe D, Choti MM, Hepatocellular carcinoma: consensus recommendations of the national cancer institute clinical trials planning meeting. J Clin Oncol 2010;28:3994-4005
   PubMed Web of Science ®Google Scholar
• Forner A, Reig ME, de Lope CR, Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010;30:61-74
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montana X, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9
   PubMed Web of Science ®Google Scholar
• Llovet JM, Di Bisceglie AM, Bruix J, Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711
   PubMed Web of Science ®Google Scholar
• Lo CM, Ngan H, Tso WK, Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71
   PubMed Web of Science ®Google Scholar
• Malagari K, Alexopoulou E, Chatzimichail K, Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging 2008;33:512-19
   PubMed Web of Science ®Google Scholar
• Reig M, Burrel M, Forner A, Resultados actuales de la quimioembolizacion en pacientes con carcinoma hepatocelular. Impacto en practica clinica e investigacion. Gastroenterol Hepatol 2011;34:139-209
   Google Scholar
• Takayasu K, Arii S, Ikai I, Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis. Am J Roentgenol 2010;194:830-7
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Cabibbo G, Enea M, Attanasio M, A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010;51:1274-83
   PubMed Web of Science ®Google Scholar
• Tam KY, Leung KC, Wang YX. Chemoembolization agents for cancer treatment. Eur J Pharm Sci 2011;44:1-10
   PubMed Web of Science ®Google Scholar
• Bismuth H, Ciche L, Adam R, Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218:145-51
   PubMed Web of Science ®Google Scholar
• Mazzaferro A, Regalia E, Doci R, Liver transplantation for the treatment of small HCC in patients with cirrhosis. N Engl J Med 1996;334:693-700
   PubMed Web of Science ®Google Scholar
• Adam R, Lucidi V, Bismuth H. Hepatic colorectal metastases: methods of improving resectability. Surg Clin North Am 2004;84:659-71
   PubMed Web of Science ®Google Scholar
• Alberts SR, Wagman LD. Chemotherapy for colorectal cancer liver metastases. Oncologist 2008;10:1063-73
   Google Scholar
• Kerr SH, Kerr DJ. Novel treatments for hepatocellular cancer. Cancer Lett 2009;286:114-20
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Clark JW, Ryan DP, A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2002;94:3186-91
   PubMed Web of Science ®Google Scholar
• Yang TS, Lin YC, Chen JS, Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000;89:750-6
   PubMed Web of Science ®Google Scholar
• Yeo W, Mok TS, Zee B, A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-8
   PubMed Web of Science ®Google Scholar
• Ramsey DE, Kernagis LY, Soulen MC, Chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiol 2002;13:S211-21
   PubMed Web of Science ®Google Scholar
• Breedis C, Young G. The blood supply of neoplasm of the liver. Am J Pathol 1954;30:969-85
   PubMed Web of Science ®Google Scholar
• Salem R, Thurston KG. Radioembolization with yttrium-90 microspheres: a state of the art brachytherapy treatment for primary and secondary liver malignancies. II. Special topics. J Vasc Interv Radiol 2006;17:1425-39
   PubMed Web of Science ®Google Scholar
• Kruskal JB, Hlatky L, Hahnfeldt P, In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol 1993;4:741-7
   PubMedGoogle Scholar
• Egawa H, Maki A, Mori K. Effects of intraarterial chemotherapy with a new lipophilic anticancer agent, estradiolchlorambucil (KM2210), dissolved in lipiodol on experimental liver tumor in rats. J Surg Oncol 1990;44:109-14
   PubMed Web of Science ®Google Scholar
• Konno T. Targeting cancer chemotherapeutic agents by use of lipiodol contrast medium. Cancer 1990;66:1897-903
   PubMed Web of Science ®Google Scholar
• Nicolini A, Fasani P, Manini MA, Transarterial embolization with microspheres in the treatment of monofocal HCC. Dig Liver Dis 2009;41:143-9
   PubMedGoogle Scholar
• Brown KT, Nevins AB, Getrajdman GI, Particle embolization for hepatocellular carcinoma. J Vasc Interv Radiol 1998;9:822-8
   PubMed Web of Science ®Google Scholar
• Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J Biol Chem 2001;276:43407-12
   PubMed Web of Science ®Google Scholar
• Tajima T, Honda H, Taguchi K, Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation. AJR Am J Roentgenol 2002;178:885-97
   PubMed Web of Science ®Google Scholar
• Gadaleta DC, Ranieri G. Trans-arterial chemoembolization as a therapy for liver tumours: new clinical developments and suggestions for combination with angiogenesis inhibitors. Crit Rev Oncol Hematol 2011;80:40-53
   PubMed Web of Science ®Google Scholar
• Ranieri G, Patruno R, Ruggieri E, Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006;13:1845-57
   PubMed Web of Science ®Google Scholar
• Li X, Feng GS, Zheng CS, Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and basic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: an experimental study. World J Gastroenterol 2003;9:2445-9
   PubMed Web of Science ®Google Scholar
• Wang B, Xu H, Gao ZQ, Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization. Acta Radiol 2008;49:523-9
   PubMed Web of Science ®Google Scholar
• Shim JH, Park JW, Kim JH, Association between increment of serum VEGF level and prognosis after transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Cancer Sci 2008;99:2037-44
   PubMed Web of Science ®Google Scholar
• Lewis AL, Dreher MR. Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy. J Control Release 2012;161:338-50
   PubMed Web of Science ®Google Scholar
• Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-61
   PubMed Web of Science ®Google Scholar
• Chan AO, Yuen MF, Hui CK, A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002;94:1747-52
   PubMed Web of Science ®Google Scholar
• Chung JW, Park JH, Han JK, Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996;198:33-40
   PubMed Web of Science ®Google Scholar
• Shin SW. The current practice of transarterial chemoembolization for the treatment of hepatocellular carcinoma. Korean J Radiol 2009;10:425-34
   PubMed Web of Science ®Google Scholar
• Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol 2007;25:978-86
   PubMed Web of Science ®Google Scholar
• Vogl TJ, Zangos S, Eichler K, Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion: an update. Eur Radiol 2007;17:1025-34
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: hepatobiliary Cancers v2. 2009. Available from: http://www.nccn.org/ [Accessed date: October 2012]
   Google Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-42
   PubMed Web of Science ®Google Scholar
• Camma C, Schepis F, Orlando A, Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224:47-54
   PubMed Web of Science ®Google Scholar
• Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011;3:CD004787
   PubMedGoogle Scholar
• Lau WY, Lai ECH. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008;7:237-57
   PubMed Web of Science ®Google Scholar
• Chern MC, Chuang VP, Cheng T, Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors. Cardiovasc Intervent Radiol 2008;31:735-44
   PubMed Web of Science ®Google Scholar
• Malagari K, Pomoni M, Kelekis A, Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010;33:541-51
   PubMed Web of Science ®Google Scholar
• Marelli L, Stigliano R, Triantos C, Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6-25
   PubMed Web of Science ®Google Scholar
• Lammer J, Malagari K, Vogl T, Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V Study. Cardiovasc Intervent Radiol 2010;33:41-52
   PubMed Web of Science ®Google Scholar
• Fiorentini G, Aliberti C, Tilli M, Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012;32:1387-95
   PubMed Web of Science ®Google Scholar
• Yamamoto J, Kosuge T, Saiura A, Effectiveness of hepatic resection for early-stage hepatocellular carcinoma in cirrhotic patients: subgroup analysis according to Milan criteria. Jpn J Clin Oncol 2007;37:287-95
   PubMed Web of Science ®Google Scholar
• Yan S, Xu D, Sun B. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci 2012;57:3026-31
   PubMed Web of Science ®Google Scholar
• Ibrahim SM, Lewandowski RJ, Sato KT, Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 2008;14:1664-9
   PubMed Web of Science ®Google Scholar
• Meza-Junco J, Montano-Loza AJ, Liu DM, Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? Cancer Treat Rev 2012;38:54-62
   PubMed Web of Science ®Google Scholar
• Cha CH, Saif MW, Yamane BH, Hepatocellular carcinoma: current management. Curr Probl Surg 2010;47:10-67
   PubMed Web of Science ®Google Scholar
• Park HC, Seong J, Han KH, Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002;54:150-5
   PubMed Web of Science ®Google Scholar
• Park W, Lim DH, Paik SW, Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005;61:1143-50
   PubMed Web of Science ®Google Scholar
• Salem R, Riaz A, Lewandowski R, Comparative effectiveness of radioembolization, the standard of care for hepatocellular carcinoma: is a randomized survival study feasible? J Clin Oncol 2010;28:4045A
   PubMedGoogle Scholar
• Poggi G, Amatu A, Montagna B, OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2009;32:1187-9
   PubMed Web of Science ®Google Scholar
• Lencioni R, Llovet JM, Han G, Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial. J Clin Oncol 2012;30(Suppl 4):abstract LBA154^
   Google Scholar
• Nakakuma K, Tashiro S, Ucrnura K, An attempt for increasing effects of hepatic artery ligation for advanced hepatoma (English abstract). Jap Deutsche Med Beriehte 1979;24:675-82
   Google Scholar
• Nakakuma K, Tashiro S, Hiraoka T, Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer 1983;52:2193-200
   PubMed Web of Science ®Google Scholar
• Nakakuma K, Tashiro S, Hiraoka T, Hepatocellular carcinoma and metastatic cancer detected by iodized oil. Radiology 1985;154:15-17
   PubMed Web of Science ®Google Scholar
• Zangan SM, Patel J. Chemoembolization for hepatocellular carcinoma. Semin Roentgenol 2011;46:105-14
   PubMed Web of Science ®Google Scholar
• Takayasu K, Shima Y, Muramatsu Y, Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 1987;163:345-51
   PubMed Web of Science ®Google Scholar
• Raoul JL, Heresbach D, Bretagne JF, Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 1992;70:585-90
   PubMed Web of Science ®Google Scholar
• Kim JH, Chung JW, Han JK, Transcatheter arterial embolization of the internal mammary artery in hepatocellular carcinoma. J Vasc Interv Radiol 1995;6:71-4
   PubMed Web of Science ®Google Scholar
• Mabed M, Esmaeel M, El-Khodary T, A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. Eur J Cancer Care 2009;5:492-9
   Google Scholar
• Kanematsu T, Inokuchi K, Sugimachi K, Selective effects of lipiodolized antitumor agents. J Surg Oncol 1984;25:218-26
   PubMed Web of Science ®Google Scholar
• Nakamura H, Hashimoto T, Oi H, Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989;170:783-6
   PubMed Web of Science ®Google Scholar
• Hino T, Kawashima Y, Shimabayashi S. Basic study for stabilization of w/o/w emulsion and its application to transcatheter arterial embolization therapy. Adv Drug Deliv Rev 2000;45:27-45
   PubMed Web of Science ®Google Scholar
• Recchia F, Passalacqua G, Filauri P, Chemoembolization of unresectable hepatocellular carcinoma: decreased toxicity with slow-release doxorubicin-eluting beads compared with Lipiodol. Oncol Rep 2012;27:1377-83
   PubMed Web of Science ®Google Scholar
• Takayasu K, Muramatsu Y, Maeda T, Targeted transarterial oily chemoembolization for small foci of hepatocellular hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates. Am J Roentgenol 2001;176:681-8
   PubMed Web of Science ®Google Scholar
• Sharma KV, Dreher MR, Tang Y, Development of “imageable” beads for transcatheter embolotherapy. J Vasc Interv Radiol 2010;21:865-76
   PubMed Web of Science ®Google Scholar
• Gaba RC, Baumgarten S, Omene BO, Ethiodized oil uptake does not predict doxorubicin drug delivery after chemoembolization in VX2 liver tumors. J Vasc Interv Radiol 2012;23:265-73
   PubMed Web of Science ®Google Scholar
• Ahmadzadehfar H, Sabet A, Wilhelm K, Iodine-131-Lipiodol therapy in hepatic tumours. Methods 2011;55:246-52
   PubMed Web of Science ®Google Scholar
• Raoul JL, Boucher E, Rolland Y, Treatment of hepatocellular carcinoma with intra-arterial injection of radionuclides. Nat Rev Gastroenterol Hepatol 2010;7:41-9
   PubMed Web of Science ®Google Scholar
• Raoul JL, Bourguet P, Bretagne JF, Hepatic artery injection of I-131-labeled lipiodol. Part I. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology 1988;168:541-5
   PubMed Web of Science ®Google Scholar
• Raoul JL, Guyader D, Bretagne JF, Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology 1997;26:1156-61
   PubMed Web of Science ®Google Scholar